ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 38366236

Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy.

Li M and 3 others. Pharm Res, 2024. Cited by 44 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy. Papers, record 38366236. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38366236

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy.
PubMed
Journal
Pharm Res
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
44
iCite
Relative citation ratio, by iCite
6.55, provisional
iCite
Revised in PubMed
2026-10-31
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li MMenghttps://orcid.org/0009-0003-1444-8375
2Zhao XXueyu
3Yu CChuanfei
4Wang LLan

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ImmunoconjugatesMajor topic
Humans
Antibodies
Drug Industry
Commerce

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References165

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131,659,006Antibody-Drug Conjugates: A Comprehensive Review.Mol Cancer Res2020https://conductscience.org/library/papers/31659006PubMed
235,305,211Bystander effect of antibody-drug conjugates: fact or fiction?Curr Oncol Rep2022https://conductscience.org/library/papers/35305211PubMed
334,045,233First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer.Mol Cancer Ther2021https://conductscience.org/library/papers/34045233PubMed
414,709,862Recent developments in the maytansinoid antitumor agents.Chem Pharm Bull (Tokyo)2004https://conductscience.org/library/papers/14709862PubMed
520,818,176Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.MAbs2010https://conductscience.org/library/papers/20818176PubMed
623,438,745Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.Chem Biol2013https://conductscience.org/library/papers/23438745PubMed
729,473,744Chemo- and Regioselective Lysine Modification on Native Proteins.J Am Chem Soc2018https://conductscience.org/library/papers/29473744PubMed
816,540,673Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.Cancer Res2006https://conductscience.org/library/papers/16540673PubMed
923,071,104Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.Mol Cancer Res2012https://conductscience.org/library/papers/23071104PubMed
1020,108,971Cancer therapies utilizing the camptothecins: a review of the in vivo literature.Mol Pharm2010https://conductscience.org/library/papers/20108971PubMed

1 to 10 of 165

See all 165 references

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 44 citations.

PMIDTitleJournalYearIn PapersSource
42,883,992From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody-Drug Conjugates.Int J Mol Sci2026https://conductscience.org/library/papers/42883992PubMed
42,840,679Spatial PK-PD mismatch in tumor-targeting antibodies and ADCs: from lesion access to pharmacologic execution.Front Oncol2026https://conductscience.org/library/papers/42840679PubMed
42,735,911Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer.Clin Transl Med2026https://conductscience.org/library/papers/42735911PubMed
42,563,409Ocular Tissue Distribution of Ocular Surface Immunoglobulin Following Topical and Subconjunctival Administration: A Novel Strategy for Mitigation of Antibody-Drug Conjugate-Associated Ocular Toxicity.J Ocul Pharmacol Ther2026https://conductscience.org/library/papers/42563409PubMed
42,559,290Antibody-Drug Conjugates and Peptide-Drug Conjugates: Current Understandings and Future Perspectives.MedComm (2020)2026https://conductscience.org/library/papers/42559290PubMed
42,449,032Raman Spectroscopy for Characterizing Monoclonal Antibody Reduction: A Process Analytical Technology Approach for Antibody-Drug Conjugation Process Development.Pharm Res2026https://conductscience.org/library/papers/42449032PubMed
42,356,477Advancements in Dual-Load Antibody-Drug Conjugates and Challenges with Quality Analysis.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42356477PubMed
42,243,572Antibody-Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations.AAPS PharmSciTech2026https://conductscience.org/library/papers/42243572PubMed
42,226,254Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection.Mol Cancer2026https://conductscience.org/library/papers/42226254PubMed
42,125,649Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review.Front Immunol2026https://conductscience.org/library/papers/42125649PubMed

1 to 10 of 32

See all 32 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38366236

GET https://conductscience.org/api/papers/v1/38366236/references?page=2

API referenceFor AI assistants